Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.

@article{DarrehShori2008InhibitionOA,
  title={Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.},
  author={Taher Darreh-Shori and Ahmadul Kadir and Ove Almkvist and Mikaela Grut and Anders E Wall and Gunnar Blomquist and Bo Eriksson and Bengt L{\aa}ngstr{\"o}m and A. Nordberg},
  journal={Neurobiology of aging},
  year={2008},
  volume={29 2},
  pages={168-84}
}
The relationship between acetylcholinesterase (AChE) activity in the CSF and brain of patients with Alzheimer's disease (AD) was investigated in 18 mild AD patients following galantamine treatment. The first 3 months of the study had a randomized double-blind placebo-controlled design, during which 12 patients received galantamine (16-24 mg/day) and six patients placebo. This was followed by 9 months galantamine treatment in all patients. Activities and protein levels of both the "read-through… CONTINUE READING